Breast Imaging

What Is the Best Imaging for Locoregional Staging of Early-Stage Breast Cancer?

·
What Is the Best Imaging for Locoregional Staging of Early-Stage Breast Cancer?

A 54-year-old woman presents to your office for consultation following a core needle biopsy that confirmed a 1.5 cm, grade 2 invasive ductal carcinoma in her right breast. Her physical exam is notable for a palpable, mobile mass corresponding to the biopsy site, with no axillary adenopathy or skin changes. She is clinically stage IB (T1c N0 M0). The immediate clinical question is how to best evaluate the extent of her locoregional disease to guide surgical planning—is this a solitary focus amenable to lumpectomy, or is there more extensive disease? For this specific scenario of newly diagnosed, clinical stage I-IIA breast cancer, the American College of Radiology (ACR) Appropriateness Criteria rate US breast as Usually Appropriate for the initial evaluation of locoregional disease.

Who Fits This Clinical Scenario for Locoregional Staging?

This guidance applies specifically to patients with newly diagnosed, biopsy-proven invasive breast cancer who are considered to have early-stage disease based on initial clinical and imaging findings.

Inclusion criteria for this workflow:

  • Diagnosis: Invasive ductal carcinoma (IDC), invasive lobular carcinoma (ILC), or invasive carcinoma not otherwise specified (NOS).
  • Clinical Stage: Stage I or IIA. This typically includes tumors (T) that are 5 cm or smaller (T1, T2) and have either no clinical evidence of lymph node involvement (N0) or only clinically detected micrometastases in the nodes (N1mi).
  • Presentation: The patient has no signs or symptoms suggesting the cancer has spread to distant sites (e.g., no new bone pain, persistent cough, or unexplained weight loss).

It is critical to distinguish this scenario from similar but distinct clinical situations that require a different imaging approach. This workflow does not apply if:

  • The patient has symptoms of distant disease: If a patient with a new breast cancer diagnosis also reports new, persistent bone pain or other systemic symptoms, the evaluation shifts. The appropriate workup would follow the ACR variant for evaluating distant disease in early-stage cancer.
  • The cancer is locally advanced: Patients presenting with larger tumors (>5 cm), inflammatory breast cancer, skin or chest wall invasion, or matted axillary lymph nodes are considered clinical stage IIB or III. This more advanced presentation requires a different locoregional and systemic staging strategy.
  • The evaluation is for recurrence: This guidance is for the initial workup. A patient with a history of breast cancer presenting with suspected local recurrence would be evaluated under the ACR’s surveillance scenarios.

What Are You Evaluating with Locoregional Imaging in Early-Stage Breast Cancer?

Once a diagnosis of invasive breast cancer is established via biopsy, the goal of subsequent imaging shifts from diagnosis to staging and surgical planning. The primary questions you are trying to answer with locoregional imaging are not about the nature of the known mass, but rather about its context and extent.

Extent of the Primary Tumor: The first goal is to accurately measure the size of the known cancer (the “index lesion”). Imaging provides a more precise measurement than physical exam alone, which is crucial for T-staging. It also assesses the tumor’s relationship to the skin, nipple, and underlying pectoral muscle to ensure adequate surgical margins can be achieved.

Multifocal or Multicentric Disease: A key determination is whether additional, separate foci of cancer exist within the same breast. Multifocal disease refers to multiple tumors within the same quadrant, while multicentric disease involves tumors in different quadrants. The presence of extensive additional disease is a primary factor in deciding between breast-conserving surgery (lumpectomy) and mastectomy.

Nodal Status: The most important prognostic factor in early-stage breast cancer is the status of the axillary lymph nodes. While a clinical exam can detect bulky nodes, imaging is far more sensitive for identifying subtle or non-palpable “occult” metastases. Identifying suspicious nodes on imaging allows for a targeted, pre-operative biopsy, which can significantly alter the surgical plan for the axilla.

Why Is Breast Ultrasound a Recommended First Step for Locoregional Staging?

For a patient with newly diagnosed Stage I-IIA breast cancer, both diagnostic mammography/tomosynthesis and breast ultrasound are rated Usually Appropriate by the ACR. Often, they are used together as complementary tools. Ultrasound, however, provides unique, real-time information critical for immediate next steps.

The primary rationale for ultrasound is its excellent ability to characterize the known mass, provide precise measurements, and evaluate the axillary lymph nodes without using ionizing radiation (0 mSv). It can clearly define the tumor’s margins and assess for satellite nodules near the index lesion. Crucially, if any additional suspicious solid masses or abnormal-appearing lymph nodes are identified, ultrasound can be used in the same session to guide a fine-needle aspiration (FNA) or core needle biopsy.

How do alternative studies compare for this specific scenario?

  • Diagnostic Mammography and Digital Breast Tomosynthesis (DBT): Also rated Usually Appropriate, these are essential for assessing the overall breast architecture, particularly for detecting suspicious microcalcifications or areas of architectural distortion that may represent ductal carcinoma in situ (DCIS) or an additional invasive focus that ultrasound might miss. Mammography and ultrasound are best viewed as partners in the initial workup.
  • MRI breast without and with IV contrast: This is also rated Usually Appropriate. While breast MRI is the most sensitive modality for detecting additional cancer foci, it is not typically the first-line tool for all early-stage patients due to higher cost, limited availability, and a higher rate of false positives that can lead to unnecessary biopsies and patient anxiety. It is often reserved for specific indications within this scenario, such as in patients with dense breast tissue or when there is a significant discrepancy between the findings on mammography/ultrasound and the clinical exam, particularly with invasive lobular carcinoma.
  • FDG-PET/CT skull base to mid-thigh: This is rated Usually Not Appropriate. For clinical stage I-IIA disease, the risk of distant metastatic disease is low. The potential benefit of whole-body staging does not outweigh the significant radiation dose (☢☢☢☢ 10-30 mSv) and the risk of false-positive findings in this patient population. Systemic staging is reserved for patients with locally advanced disease or clinical suspicion of metastases.

What’s the Next Step After Initial Locoregional Imaging?

The results of the diagnostic mammogram and targeted breast and axillary ultrasound will direct the subsequent clinical workflow and surgical plan.

  • Finding: Solitary tumor, no suspicious axillary nodes. If imaging confirms a single focus of cancer corresponding to the biopsy site and the axillary lymph nodes appear normal, the patient can proceed directly to surgical consultation. The likely plan will be breast-conserving therapy (lumpectomy) combined with a sentinel lymph node biopsy procedure to pathologically stage the axilla.
  • Finding: Additional suspicious lesion(s) in the breast. If ultrasound or mammography identifies one or more additional suspicious masses, the next step is an image-guided biopsy of these new findings. If biopsy confirms additional sites of cancer, particularly in different quadrants (multicentric disease), the patient may no longer be a candidate for lumpectomy and may be counseled towards a mastectomy.
  • Finding: Suspicious axillary lymph node(s). If axillary ultrasound reveals a lymph node with suspicious features (e.g., cortical thickening, rounded shape, loss of the fatty hilum), an ultrasound-guided FNA or core biopsy of that node is required. A positive biopsy confirms nodal metastasis (N1 disease), which upstages the patient. This information is critical, as it may prompt the surgeon to perform a more extensive axillary lymph node dissection instead of or in addition to a sentinel node biopsy.
  • Finding: Indeterminate or conflicting results. In cases where the extent of disease is unclear—for example, in a patient with extremely dense breasts or with invasive lobular carcinoma where tumor size is difficult to assess—the next step is often to proceed with the other Usually Appropriate modality: MRI breast without and with IV contrast. MRI can help clarify the true disease extent and guide a definitive surgical plan.

Common Pitfalls in Early-Stage Breast Cancer Imaging

Navigating the initial workup for early-stage breast cancer requires careful integration of clinical and imaging findings. Several common pitfalls can lead to incomplete staging or suboptimal treatment planning.

  • Underestimating Invasive Lobular Carcinoma (ILC): ILC has a tendency to grow in single-file lines of cells, which may not form a discrete mass on mammography or ultrasound. This can lead to a significant underestimation of the tumor’s true size. Maintain a high index of suspicion and a low threshold for ordering a breast MRI if the clinical exam suggests a larger area of concern than is visible on initial imaging.
  • Incomplete Axillary Evaluation: A “breast ultrasound” order should always be interpreted to include a thorough evaluation of the axilla. Failing to meticulously scan for and characterize axillary lymph nodes can miss clinically occult metastases, potentially subjecting a patient to a second axillary surgery after initial sentinel node biopsy results are known.
  • Stopping the Workup Prematurely: Identifying an additional suspicious lesion on imaging is not the end of the workup. A definitive surgical plan should not be made until all suspicious findings have been biopsied and pathologically characterized. Proceeding to surgery based on assumptions can lead to positive margins and the need for re-excision. If imaging findings are equivocal, escalate to the next appropriate study (often MRI) or multidisciplinary tumor board discussion.

Related ACR Topics and Tools

For a comprehensive overview of all clinical variants related to this topic, please see the parent article. Additional tools from GigHz can help you apply these criteria in your practice.

Frequently Asked Questions

Why is breast MRI also ‘Usually Appropriate’ but not always the first choice for Stage I-IIA cancer?

Breast MRI is the most sensitive test for detecting additional cancer foci. However, it is more expensive, less available, and has a higher rate of false positives, which can lead to additional imaging and unnecessary biopsies. It is typically reserved for specific situations, such as for patients with very dense breasts, a diagnosis of invasive lobular carcinoma, or when other imaging is inconclusive.

Is an axillary ultrasound always necessary for a small, early-stage breast cancer?

Yes. A thorough ultrasound evaluation of the axillary lymph nodes is a critical component of the initial locoregional staging, even for small tumors. It can detect clinically occult (non-palpable) nodal metastases, and a pre-operative, ultrasound-guided biopsy of a suspicious node can provide crucial information that directly impacts the surgical plan for the axilla.

When should I order a PET/CT or bone scan for a newly diagnosed breast cancer?

According to the ACR, systemic staging with PET/CT or a bone scan is ‘Usually Not Appropriate’ for asymptomatic patients with clinical stage I-IIA breast cancer. The likelihood of finding distant metastases in this group is very low, and these tests carry a significant radiation dose and risk of false positives. They are reserved for patients with more advanced disease (Stage IIB-III) or those who have symptoms concerning for metastatic spread.

If the initial mammogram was a screening study, is a diagnostic mammogram still needed?

Yes. After a biopsy confirms cancer, a full diagnostic mammogram is required. This includes standard views plus additional compression or magnification views of the area of concern and the rest of the breast. This allows for detailed characterization of the index lesion and a thorough search for other suspicious findings, like microcalcifications, that may not have been fully evaluated on the screening images.

Does contrast-enhanced mammography (CEM) have a role in this scenario?

Contrast-enhanced mammography is an emerging technology rated as ‘May be appropriate’ by the ACR for this scenario. It provides functional information similar to an MRI by highlighting areas of abnormal blood flow. It can be a useful alternative to MRI for problem-solving or staging, particularly in facilities where MRI access is limited, but it is not yet considered a primary, first-line tool in most standard workflows.

Reviewed by Pouyan Golshani, MD, Interventional Radiologist — May 30, 2026